The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
May 13, 2024
View Complete Issue         Table of Contents 2019 
Erdafitinib (Balversa) for Urothelial Carcinoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Erdafitinib (Balversa) for Urothelial Carcinoma (online only)
May 13, 2024 (Issue: 1702)
Erdafitinib (Balversa – Janssen), an oral kinase inhibitor, has received full approval from the FDA for treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3 (fibroblast growth factor receptor)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Erdafitinib (Balversa) for Urothelial Carcinoma (online only)
Article code: 1702g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.